Select Language
IFN-gamma R1
IFN-gamma R1 Overview
| English Name | Interferon gamma receptor | Approved Drugs | 11 |
| Drugs in Clinical Trials | 2 | Target Synonym | |
| Highest Development Stage | Approved | ||
| English Name | Interferon gamma receptor |
| Target Synonym | |
| Approved Drugs | 11 |
| Drugs in Clinical Trials | 2 |
| Highest Development Stage | Approved |
IFN-gamma R1 Product List
- Product Category
Protein (2)
- Product Status
Launched (2)
- Species
Human (2)
- Tag
Fc Tag (1)His Tag (1)
- Conjugate
Unconjugated (2)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|---|
IF1-H5223 |  Human | HEK293 | Human IFN-gamma R1 / IFNGR1 Protein, His Tag |  |  |  |
IF1-H5254 | Human | HEK293 | Human IFN-gamma R1 / IFNGR1 Protein, Fc Tag |  | | |
Total: 2
- 1
IFN-gamma R1 Background
Interferon gamma receptor 1 (IFNGR1) is also known as CD antigen CD119, which belongs to the type II cytokine receptor family. IFNGR1 contains two fibronectin type-III domains and two Ig-like C2-type (immunoglobulin-like) domains. IFNGR1 / CD119 is receptor for interferon gamma. Two receptors bind one interferon gamma (IFNG) dimer.
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| rSIFN-co | Phase 3 Clinical | Sichuan Huiyang Life Science and Technology Corp | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colonic Neoplasms; Colorectal Neoplasms; Coronavirus Disease 2019 (COVID-19); Hepatitis B, Chronic; Lung Neoplasms; Melanoma; Neuroendocrine Tumors; Prostatic Neoplasms | Details | |
| Interferon gamma (aerosol, IPF/ COPD), Stony Brook University School of Medicine | Phase 2 Clinical | Nostrum, Nyu Langone Medical Center, Stony Brook University School Of Medicine | Pulmonary Disease, Chronic Obstructive | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Interferon gamma biosimilar (Livzon Pharmaceutical Group) | Approved | Livzon Pharmaceutical Group Inc | Mainland China | Arthritis, Rheumatoid | Livzon Pharmaceutical Group Inc | 1998-01-01 | Arthritis, Rheumatoid | Details | ||
| Interferon gamma (Hayashibara) | OH-6000 | Approved | Hayashibara | Ogamma | Japan | Skin Neoplasms | null | 1997-08-05 | Skin Neoplasms | Details |
| Recombinant interferon gamma (Shanghai Chemo Wanbang Biopharma) | Approved | Shanghai Kaimao Bio-Pharmaceutical Co Ltd | gamma, 伽玛 | Mainland China | Arthritis, Rheumatoid; Liver Cirrhosis | Shanghai Kaimao Bio-Pharmaceutical Co Ltd | 1998-01-01 | Arthritis, Rheumatoid; Granulomatous Disease, Chronic; Liver Cirrhosis | Details | |
| Interferon gamma-1a biosimilar (Shionogi) | S-6810 | Approved | Shionogi & Co Ltd | Imunomax-γ | Japan | Mycosis Fungoides; Carcinoma, Renal Cell; Myocardial Infarction; Communicable Diseases | Shionogi & Co Ltd | 1989-09-29 | Carcinoma, Renal Cell; Communicable Diseases; Mycosis Fungoides; Myocardial Infarction | Details |
| Interferon gamma-1b | DasKloster-1001; DasKloster-1001-01; AMG-292 | Approved | Genentech Inc | Imukin 1, Actimmune, Immukin | United States | Osteopetrosis; Granulomatous Disease, Chronic | Horizon Therapeutics Ireland Dac | 1999-02-25 | Adenocarcinoma, Mucinous; Aspergillosis; Candidemia; Colonic Neoplasms; Cystic Fibrosis; Eye Diseases, Hereditary; Friedreich Ataxia; Granulomatous Disease, Chronic; Hepatitis C, Chronic; HIV Infections; Idiopathic Pulmonary Fibrosis; Leukemia, Myeloid, Acute; Liver Cirrhosis; Lung Diseases; Macular Degeneration; Melanoma; Mycobacterium avium-intracellulare Infection; Myelodysplastic Syndromes; Osteopetrosis; Plaque psoriasis; Pneumonia; Pulmonary Aspergillosis; Pulmonary Fibrosis; Rectal Neoplasms; Retinal Degeneration; Retinal Diseases; Tuberculosis, Pulmonary; Uveitis; Uveitis, Anterior | Details |
| Interferon biosimilar (LG Life Sciences) | Approved | Lg Chemical Ltd | Leukemia | Lg Chemical Ltd | 1989-01-01 | Leukemia | Details | |||
| Interferon gamma-1a (Asubio Pharma) | SUN-4800 | Approved | Asubio | Biogamma | Japan | Mycosis Fungoides | Asubio | 1992-01-01 | Mycosis Fungoides | Details |
| Interferon gamma biosimilar (Pharmaclon) | Approved | Pharmaclon | Ingaron | Russian Federation | Tuberculosis, Pulmonary; Influenza, Human; HIV Infections; Hepatitis B; Herpes Zoster; Warts; Hepatitis C; Chlamydia Infections; Neoplasms; Respiratory Distress Syndrome, Newborn; Prostatitis | Pharmaclon | 2011-01-01 | Chlamydia Infections; Condylomata Acuminata; Hepatitis B; Hepatitis C; Herpes Zoster; HIV Infections; Influenza, Human; Lentivirus Infections; Neoplasms; Papillomavirus Infections; Prostatitis; Respiratory Distress Syndrome, Newborn; RNA Virus Infections; Tuberculosis, Pulmonary; Warts | Details | |
| Interferon Gamma (Materia Medica Holding) | Approved | Materia Medica Holding Research And Production Company | Anaferon | Bacterial Infections; Virus Diseases | Details | |||||
| Interferon gamma biosimilar (Center for Genetic Engineering and Biotechnology) | Approved | Center For Genetic Engineering And Biotechnology | Idiopathic Pulmonary Fibrosis; Tuberculosis | Details | ||||||
| Interferon gamma biosimilar (Recpharma) | Approved | Recpharma | IMMUNEX | Granulomatous Disease, Chronic; Neoplasms; Osteoporosis; Virus Diseases | Details |
- Overview
- Product List
- Marketed Drug Information
- Clinical Drug Information
Share to:
Online Message
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland